The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is an industry-unique drug discovery biotech with a diverse group of passionate, dedicated and collaborative scientists committed to helping eradicate Alzheimer’s disease. Recognizing the potential for human genetics, data sciences and precision chemistry to disrupt the drug discovery paradigm, Eisai established G2D2 to accelerate the discovery of innovative therapeutics. G2D2 is committed to accelerating drug discovery premised upon robust insights from human biology, and driving multi-disciplinary team-based progress towards addressing real unmet patient needs. G2D2 is a science-first organization with one goal: deliver breakthroughs for dementia patients and their families. We prioritize multi-disciplinary innovation and collaboration to accelerate achieving our mission.
Advances in human genetics and data sciences enable discovery and development of novel therapeutics with increased odds of success. At G2D2, we focus not only on how such data help identify and validate therapeutic targets, but also to guide novel approaches to drug such targets and match them to the right patient at the right time. Our precision chemistry strategy - in the context of insights from human genetics - is uniquely positioned to deliver tailor-designed small molecule, anti-sense oligo-nucleotide, and other solutions for targeted therapeutics.
Our new cutting-edge 50,000-square-foot facility is strategically located in Cambridge, MA, to accelerate collaborations with leading research institutes in this world-class biotech hub. Our facility has been designed around a novel open-lab concept, enabling chemists, biologists, automation and other scientists to work together in a single common and integrated lab space. Our labs include state-of-the-art capabilities in medicinal and process chemistry, in-vitro and in-vivo biology, microscopy, chemical and structural biology, automation and screening, and several other discovery technologies and platforms. Our office is designed to foster an atmosphere of mission-driven and collaborative science, using several new collaboration tools and technologies, with an emphasis on data-sciences. The atmosphere of our facility emphasizes innovation through active day-to-day interactions that eliminate traditional scientific silos. Our lab, office and recreational spaces enhance real-time information sharing and team-based science.
The predominant research focus at G2D2 is Immunodementia: novel immune-related targets for dementia validated by human genetics. Our approach is premised upon and continuously incorporates robust insights from human genetics and other sources of human biology. This research focus builds upon Eisai's considerable experience in and commitment to neurology research, and to our human health care mission, which recognizes the profound impact of Alzheimer's and related dementia on patients and their caregivers.
You will join a highly interactive and collaborative team spanning a broad range of drug discovery capabilities including, data sciences (including genetics and informatics), wet lab biology (in-vitro and in-vivo), drug discovery platforms (biochemistry, chemical biology, assay development, structural biology, screening, drug safety and DMPK), and chemistry (including application of novel small molecule and anti-sense oligonucleotide approaches).
At Eisai, we highly value both internal and external collaboration and pursue flexible research models with a range of external scientific partners to accelerate delivery of innovative medicines. To this end, the G2D2 facility includes the Eisai Incubator for Neurodiscovery (e-IND), which provides space and infrastructure to start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.
As an Eisai employee you will spend at least 1% of your working time with patients and families to ensure that the innovation you drive is based on an understanding of their real needs.
More information about G2D2 is provided here (http://eisai.mediaroom.com/2018-06-12-Eisai-Inc-to-Launch-Center-for-Genetics-Guided-Dementia-Discovery-in-Cambridge-Massachusetts) and here (https://us.eisai.com/research/g2d2), and about Eisai's Neurology strategy and pipeline are provided here (https://www.eisai.com/index.html).
Postdoctoral Fellowships in Genetics and NeurodiscoveryThis new and highly applied training program is targeted at researchers potentially interested in a career in drug discovery and considering transitioning from academia into industry. The focus of the program is three-fold:(i) Conduct cutting-edge, high-quality and impactful scientific research(ii) Receive expert training in key scientific technologies and strategies relevant to drug discovery (iii) Gain broad exposure to drug discovery and development within an industry setting The Fellow will spend approx. 20% of their time gaining “end-to-end” exposure to all aspects of drug discovery and development (spanning discovery, translational, clinical, and commercial), attending relevant scientific conferences and training seminars, and presenting and disseminating their research. The remaining 80% of their time will be spent embedded within drug discovery research teams, and will focus on addressing priority scientific questions to impact drug discovery programs and platforms.The Postdoctoral Fellow will have a dedicated internal supervisor within Eisai with experience and expertise relevant to their research theme. In addition, the Fellow will have the opportunity to receive guidance from an external academic mentor. This is a unique opportunity for talented and collaborative early-career scientists interested in learning about drug discovery
Current Postdoctoral Fellowship OpportunitiesSuccessful translation of findings from analysis of human data into the wet lab and back is a foundation of G2D2’s approach to drug discovery. A particular focus of our Data Science & Scientific Infrastructure (DS&SI) team is analysis of human genetic data to inform target identification/validation, design and prioritization of compound screening, biomarker identification/validation, and clinical trial design. We welcome applicants with experience at the interface of genetics and experimental biology. Research activities may include: (1) Applying novel statistical genetics methods to large scale human genetic datasets to identify novel targets and biomarkers(2) Designing and performing experiments to functionally screen genetic variants in relevant model systems (3) Performing follow-on experiments to prioritize among potential targets or biomarkers Qualified candidates will possess a PhD.
Eisai is committed to a policy of equal employment opportunity for all employees and applicants. The Company also strives for a work environment free from discrimination and harassment. It is Eisai’s policy to comply with all applicable federal, state and local laws and regulations regarding nondiscrimination in employment and not to discriminate against any employee or applicant for employment on the basis of any protected status, including, but not limited to, race, color, national origin, religion, sex, age, disability, pregnancy, ancestry, creed, alienage or citizenship status, sexual orientation, gender identity and expression, marital status, military/veteran status, genetic information, or any other protected characteristic as established by law. Eisai is an Equal Opportunity Employer – Minority / Female / Disability / Veteran
Please copy-paste the below link to web browser to apply -